Search - tctmd.com

Displaying 681 - 700 of 707

Sort: Relevancy | Date

News Daily News

Double-Dose Clopidogrel Reduces Infarct Size in STEMI Patients

September 26, 2011

News Daily News

Ticagrelor Gains FDA Approval for Use in ACS

July 22, 2011

News Industry News

FDA Approves New Medicine BRILINTA™ (Ticagrelor) for Use in the US

July 20, 2011

News Daily News

HORIZONS-AMI: Bivalirudin Reduces Cardiac Death in Diabetics

July 18, 2011

News Daily News

Study Examines Predictors of Thrombus Aspiration Failure in Primary PCI

June 22, 2011

News Daily News

Canada Approves Ticagrelor in ACS Patients

June 02, 2011

News Industry News

Health Canada approves BRILINTA (ticagrelor tablets)

June 01, 2011

News Daily News

PLATO Substudy: Excess Arrhythmias with Ticagrelor Have No Clinical Impact

May 02, 2011

News Daily News

LANCELOT: Antiplatelet Agent Shows Positive Signs in Patients With ACS, Stable CAD

April 21, 2011

News Conference News

Radial vs. Femoral Angioplasty: Still RIVALs

April 04, 2011

News Daily News

Nonaccess Site Bleeding After PCI Strongly Tied to Long-term Mortality

March 08, 2011

News Daily News

High-Dose Maintenance Clopidogrel Lowers Platelet Reactivity, Other Risk Factors

February 06, 2011

News Daily News

Ticagrelor More Effective Than Clopidogrel in ACS-With No Extra Bleeding

August 30, 2009

News Daily News

JUPITER: Rosuvastatin Cuts Heart Risk, Even In LDL-Normal Patients

November 11, 2008

Balancing Ischemic and Bleeding Risk with Antiplatelet Therapy: Personalizing Treatment to Optimize Outcomes

CME

Balancing Ischemic and Bleeding Risk with Antiplatelet Therapy: Personalizing Treatment to Optimize Outcomes

PLX Pharma - Aspirin for the Interventionalist: More Than Meets the Eye

CME

Aspirin for the Interventionalist: More Than Meets the Eye

Everyday Antiplatelet Decisions: Making the Right Choices

CME

Everyday Antiplatelet Decisions: Making the Right Choices

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.